Related Experiment Video
Updated: Mar 1, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Antiproliferative Drugs for Restenosis Prevention
Anwer Habib1, Aloke Virmani Finn2
1Division of Cardiology, Department of Internal Medicine, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA.
Insights
Drug-eluting stents help prevent restenosis after angioplasty but can delay healing. New stent technologies are needed to improve vascular healing and reduce complications for cardiovascular disease patients.
Area of Science:
- Cardiovascular medicine
- Biomedical engineering
- Pharmacology
Background:
- Cardiovascular disease is a major global health concern.
- Obstructive vascular disease is often treated with drug-eluting stents (DES).
- DES inhibit smooth muscle cell proliferation to prevent restenosis.
Purpose of the Study:
- To highlight the limitations of current DES.
- To discuss the impact of DES on re-endothelialization and vascular healing.
- To suggest the need for improved DES technologies.
Main Methods:
- Review of current literature on DES.
- Analysis of drug elution mechanisms and cellular responses.
- Comparison of endothelial and smooth muscle cell proliferation inhibition.
Main Results:
- Current DES drugs inhibit both smooth muscle cells and endothelial cells.
- Delayed re-endothelialization can impede vascular healing.
- This non-specific inhibition poses a risk for patients.
Conclusions:
- Existing DES drug formulations hinder optimal vascular healing.
- There is a critical need for novel DES strategies.
- Future DES should promote healing while preventing restenosis.
Abstract:
Cardiovascular disease is a leading cause of death and disability worldwide. Current treatment strategies aimed at treating the symptoms and consequences of obstructive vascular disease have embraced both optimal medical therapy and catheter-based percutaneous coronary intervention with drug-eluting stents. Drug-eluting stents elute antiproliferative drugs inhibiting vascular smooth muscle cell proliferation, which occurs in response to injury and thus prevents restenosis. However, all drugs currently approved for use in drug-eluting stents do not discriminate between proliferating vascular smooth muscle cells and endothelial cells, thus delaying re-endothelialization and subsequent vascular healing.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Coronary Artery Disease V: Interprofessional Care
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...